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Abstract
Background—Ethical principles obligate researchers to maximize study participants’ 
comprehension during the informed consent process for clinical trials. A pilot evaluation of the 
consent process was conducted during an international clinical trial of treatment for pulmonary 
tuberculosis to assess the feasibility of conducting an evaluation in a larger population and to 
guide these future efforts.
Methods—Study staff administered an informed consent assessment tool (ICAT) to a 
convenience sample of trial participants, measuring comprehension of consent components as 
derived from the Common Rule and FDA Title 21 Part 50, and satisfaction with the process. 
Participating site staff completed a consent process questionnaire about consent practices at their 
respective sites and provided improvement recommendations. ICAT scores and corresponding 
practices were compared where both were completed.
Results—ICATs (n = 54) were submitted from one site in Spain (n = 10), one in Uganda (n = 
30), and five in the United States (n = 14). Participants were primarily male (76%), born in Africa 
(n = 31, 57%), and had a median age of 27 years (interquartile range [IQR]: 24–42). Median ICAT 
scores were 80% (IQR: 67–93) for comprehension and 89% (IQR: 78–100) for satisfaction. 
Ugandan participants scored higher than participants from other sites on comprehension (87% vs. 
64%) and satisfaction (100% vs. 78%). Staff from 14 sites completed consent process 
questionnaires. Median ICAT scores for comprehension and satisfaction were higher at sites that 
utilized visual aids. Practice recommendations included shorter forms, simpler documents, and 
supplementary materials.
Conclusions—Participants achieved high levels (≥80%) of comprehension and satisfaction with 
their current consent processes. Higher ICAT scores at one site suggest an additional evaluation 
may identify approaches to improve comprehension and satisfaction in future trials. Through this 
pilot evaluation, complexities and challenges were identified in obtaining consent in a large, 
international multicenter trial and provided insights for a more robust assessment of the consent 
process in future trials.
Keywords
Comprehension; informed consent; satisfaction; tuberculosis
The informed consent process is a fundamental part of research and is intended to explain 
and communicate the risks and rights of participants in clinical trials (U.S. Department of 
Health and Human Services 2009a; 2011a). Ethical guidelines pertaining to the protection of 
human subjects, as enumerated in the Belmont Report, include three principles to guide the 
conduct of clinical trials: respect for persons, beneficence, and justice (National Commission 
for the Protection of Human Subjects of Biomedical and Behavioral Research 1979). U.S. 
federal regulations under the Department of Health and Human Services, Title 45 Part 46 of 
the Code of Federal Regulations (45 CFR 46), subpart A, known as the “Common Rule,” 
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and the Food and Drug Administration (FDA) Title 21 Part 50 (21 CFR 50) specify required 
elements that investigators must describe when they recruit and seek consent from a 
prospective study participant (Chanaud 2008; U.S. Department of Health and Human 
Services 2009; 2011a; 2013).
Presentation of these components should occur
under circumstances that provide the prospective subject or the representative 
sufficient opportunity to consider whether or not to participate and that minimize 
the possibility of coercion or undue influence. (U.S. Department of Health and 
Human Services 2009)
Nevertheless, studies of informed consent in clinical trials have that found some patients 
have limited understanding of the content presented during the consent process (Breese et al. 
2007; Crepeau et al. 2011; Hill et al. 2008; Joffe et al. 2001). In response, researchers have 
proposed alternative methods, including cognitive interviewing techniques, visual aids, 
culturally appropriate resources, and attention to the oral presentation of the informed 
consent process’s key elements (Breese et al. 2007; Yates et al. 2009).
The Tuberculosis Trials Consortium (TBTC) is sponsored by the Division of Tuberculosis 
Elimination of the U.S. Centers for Disease Control and Prevention (CDC) (Sandman et al. 
2006). TBTC’s informed consent process has been evaluated previously (Breese et al. 2007; 
Burman et al. 2003). In light of the U.S. Department of Health and Human Services (DHHS) 
proposed changes to the Common Rule to accommodate multicenter studies and address the 
expansion of research involving human participants in new scientific disciplines and venues 
as well as technical adjustments proposed by the Federal Advance Notice of Proposed 
Rulemaking to improve the forms and processes used for informed consent (U.S. 
Department of Health and Human Services and Office of the Secretary 2011), TBTC 
committed itself to further evaluation of the consent process across the consortium.
Advocating on behalf of research participants, TBTC’s Community Research Advisory 
Group (CRAG) supported the proposed evaluation efforts. Specifically, CRAG advised that 
from the perspective of participants, the process for obtaining informed consent was just as 
important as the statements and specific wording in the consent forms. They suggested 
TBTC should further evaluate participant comprehension and satisfaction of the process and 
explore site-specific processes. Additionally, CRAG members hypothesized that the trial site 
in Kampala, Uganda, provided a useful comparison group because (1) the site has been the 
consortium’s highest enrolling site for a number of studies, enrolling approximately half of 
the participants in the clinical trial in which this evaluation was embedded, and (2) the site’s 
two-step informed consent process, which entailed introducing general research principles to 
a prospective study participant on one day and presenting study-specific details on another 
day, may be an innovative approach to maximizing participant comprehension and 
satisfaction. Comparing the practices at the Uganda site with those at other sites may help to 
demonstrate which consent practices are associated with differences in comprehension and 
satisfaction.
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The objectives of this pilot evaluation were to measure participant comprehension and 
satisfaction of the informed consent process in a large, international, multicenter site 
research study, using an adapted informed consent assessment tool (ICAT) (Breese et al. 
2007); gather information about the consent processes at the study sites in a clinical trial; 
and compare ICAT scores with corresponding site consent practices.
Limited empirical research exists on the administration, comprehension, and satisfaction of 
informed consent (Kass, Maman, and Atkinson 2005) as part of international clinical trials. 
Much of the published consent research is derived from studies that have employed 
hypothetical scenarios or from studies conducted in developed countries and among study 
participants with relatively high levels of education (Montalvo and Larson 2014; Nishimura 
et al. 2013). Breese et al. (2007) helped demonstrate the importance of evaluating the effects 
of education level on informed consent comprehension and satisfaction (Breese et al. 2007). 
The project described in this report collected data from persons with an infectious disease of 
major public health importance (World Health Organization 2014) that largely affects 
marginalized groups (Centers for Disease Control and Prevention 2013) and evaluated 
participants enrolled in a multisite, international trial. In addition to identifying strengths and 
weakness of existing consent practices, this project aimed to assess this evaluation approach 
so as to guide evaluation efforts in future studies.
METHODS
Study Population
From December 2008 through November 2010, TBTC sites enrolled participants into an 
international, open-label, randomized Phase 2 clinical trial assessing the safety and activity 
of rifapentine, a long-acting rifamycin antibiotic, in comparison to the standard drug 
rifampin, during the first 2 months of treatment for pulmonary tuberculosis (TB) (Dorman et 
al. 2012).
As required for all clinical trials, participants who agreed to enroll were asked to provide 
informed consent, which was based on the elements of 45 CRF 46 (Common Rule) and 21 
CFR 50 (U.S. Department of Health and Human Services 2009; 2013). Between August 
2009 and November 2010, participants enrolled in the clinical trial were asked to answer 
ICAT questions to measure comprehension and satisfaction with the informed consent 
process. Site staff chose study participants for ICAT administration by convenience. ICATs 
were administered only to persons who already had enrolled in the clinical trial. A volunteer 
staff member at participating sites also completed an open-ended questionnaire about their 
site-specific consent process. All site staff members enrolling in the clinical trial were 
invited to participate in this evaluation.
Ethics Statement
TBTC Study 29, the clinical trial within which this project was conducted, was approved in 
May 2008 by the institutional review boards (IRBs) of the CDC and participating 
institutions, and was registered with ClinicalTrials.gov (Study 29: NCT00694629). Some 
local IRBs ceded oversight of the TBTC protocols to the CDC’s IRB (U.S. Department of 
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Health and Human Services 2009). For this project, the CDC’s National Center for HIV/
AIDS, Viral Hepatitis, STD, and TB Prevention determined that the assessment of the 
consent process constituted a program evaluation and did not require IRB review (Centers 
for Disease Control and Prevention 2010). Additionally, each site followed local review 
policies and procedures.
Informed Consent Assessment Tool
The original Informed Consent and Authorization Assessment Tool (ICAAT) was developed 
and validated by Breese et al. (2007) to assess participants’ comprehension and satisfaction 
with the consent process. The ICAAT contained 28 items to determine how persons from 
diverse backgrounds experience the consent process. It included 21 items to assess 
comprehension of representative required elements of informed consent and seven items to 
assess satisfaction with the process (Breese et al. 2007). The ICAAT was designed to be self-
administered with three response options for each question (“Agree,” “Not Sure,” and 
“Disagree”) and included one set of paired questions that required opposite answers to 
assess the consistency of responses. For subsequent uses, questions pertinent to the Health 
Insurance Portability and Accountability Act (HIPAA) were deleted (Breese, personal 
communication) and the tool was renamed the Informed Consent Assessment Tool (ICAT) 
(Breese et al. 2007).
For this evaluation, the ICAT questions were adapted from a written, self-administered 
format to a verbal, interviewer-administered format in an effort to reduce barriers related to 
low literacy (Supplement 1). The ICAT was simultaneously translated into the participant’s 
language by the ICAT administrator, if needed. Study staff members, other than those who 
had administered informed consent, administered ICATs.
The adapted ICAT used in this evaluation contained 15 questions assessing comprehension 
of required consent components and nine evaluating participant satisfaction with the consent 
process (Supplement 1). Three response options (“Yes,” “No,” and “Not Sure”) were 
provided for each item. “Not sure” responses were grouped with the incorrect/unfavorable 
responses for analysis. Three questions were repeated in slightly modified versions to 
measure response consistency (Q.3 and Q.11; Q.6 and Q16; Q.10 and Q.17). ICATs were 
administered once during the 8-week intensive study phase when participants underwent 
clinical evaluations every 2 weeks. Participant scores were calculated based on the 
percentage of correct responses for comprehension (out of 15) or favorable responses for 
satisfaction (out of nine). ICAT scores equal to or greater than 80% were considered high.
Consent Process Questionnaire
To assess the informed consent process at each site, researchers created a 27-item, open-
ended questionnaire, based on the informed consent process used at the TBTC study site in 
Kampala, Uganda (Supplement 2). Questionnaire items included inquiries about site staff 
who administered the consent process, the use of interpreters, time spent administering 
consent, the number of visits to complete the consent process, and the approaches for 
obtaining consent from persons with low literacy. Additional items addressed approaches to 
assess participant understanding such as the use of short forms or translated forms, the use 
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of visual aids, the presence or absence of family and friends during the consent process, and 
protocols related to a participant signing the form. Suggestions for improving the informed 
consent process were also solicited.
Data Analysis
Comprehension and satisfaction scores at the site in Kampala, Uganda, were compared to 
other sites with the Wilcoxon rank-sum test (Hollander, Wolfe, and Chicken 2013); a p-value 
<.05 was considered statistically significant (SAS v. 9.3, SAS Institute, Cary, NC). Medians 
and nonparametric tests were used for a more conservative approach in this evaluation.
Answers to the site consent process questionnaire were evaluated by identifying common 
themes among the responses, tabulated for comparison, and reviewed by three of the 
investigators. Finally, among sites where both informed consent practices and ICATs were 
reported, median ICAT scores were compared by reported consent practices to determine 
which practices were related to higher comprehension and satisfaction scores.
RESULTS
The clinical trial included 24 TBTC sites and 531 enrolled patients (Figure 1). Fifteen of the 
24 sites participated by completing one or both of the data collection tools. ICATs were 
administered to 54 participants at seven (29%) of the 24 sites. These 54 participants 
represent 76% of the 71 potential participants from the seven sites during the ICAT 
collection period. There were differences in the distribution of age, birthplace, and screening 
country between the 17 participants who were eligible for ICAT administration but did not 
respond and the 54 participants who did respond (data not shown). Information regarding the 
reasons for these individuals’ nonparticipation was not available, and the small numbers 
limit the value of additional formal comparisons.
Site process questionnaires were completed at 14 sites. Six sites participated in the 
collection of both instruments by completing the consent process questionnaire and 
administering 51 ICATs. At one site, ICATs were administered to three patients but a 
questionnaire was not completed. While all site staff were invited to participate, some 
declined because the site did not have additional capacity to participate in activities outside 
of the initial protocol procedures or because local IRBs required additional approval for the 
evaluation.
Demographics
ICATs were collected by site staff in 2010 at one site in Spain (10 ICATs), one site in 
Uganda (30 ICATs), and five sites in the United States (14 ICATs). Participants (Table 1) 
were primarily male (76%) with a median age of 27 years (interquartile range [IQR]: 24–
42), with the majority having a 12th-grade education or less (n = 42, 78%). Seventeen 
percent (n = 9) reported that they had at least some college education; 6% (n = 3) reported 
education as “other,” with no further information.
ICATs were completed in the same language in which participants had discussed informed 
consent, with the possible exception of one participant for whom the language used to 
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administer the ICAT was not specified. The majority of ICATs from the Kampala, Uganda, 
site were completed on the day of enrollment, whereas at other sites, ICATs were completed 
an average of 15 days after enrollment.
Comprehension and Satisfaction of Consent Process: ICAT Scores
The median ICAT scores were 80% (IQR: 67–93) on the comprehension scale and 89% 
(IQR: 78–100) on the satisfaction scale. The median comprehension score for participants in 
Kampala (87%, IQR: 80–93) was higher than the median for those enrolled at other sites 
(64%, IQR: 57–87) (p = .002 by the Wilcoxon rank-sum test); this was also true for 
satisfaction scores with 100% (IQR: 89–100) as the median score for those enrolled in 
Kampala and 78% (IQR: 67–100) for those enrolled at other sites (p = .017). For the three 
paired ICAT questions, 67% (36/54) of the responses were consistent for comprehension 
questions 3 and 11, and 82% (44/54) of the responses were consistent for comprehension 
questions 6 and 16. For the satisfaction questions 10 and 17, 87% (47/54) of the responses 
were consistent.
For seven of the 15 ICAT comprehension questions, the overall proportion of correct or 
favorable responses was less than 80% (Table 2). Fifty-seven percent of individuals were 
unclear about whether their private information could be seen by any medical person (ICAT 
Q.9), and 22% were unclear that their names could not be used in presentations of the study 
findings (Q.14). In responding to the paired questions (Q.6 and 16) about whether study staff 
could contact friends or family without their approval, 48% and 33% did not reply with a 
correct or favorable response. At least a quarter of participants did not demonstrate a clear 
understanding that they could terminate study participation at any time (Q.11: 26%) and that 
they could receive medical care elsewhere to treat their disease (Q.22: 35% and Q.24: 28%). 
For the satisfaction questions, almost all questions had a favorable response (≥80%), except 
for one question where one-third of the participants were unsure or agreed that there was too 
much information in the consent forms (Q.2).
The overall median ICAT score for comprehension for those reporting an eighth-grade 
education or less was 67% (IQR: 60–87); participants with more than an eighth-grade 
education but no college scored 80% (IQR: 70–93); and those with at least some college 
scored 87% (IQR: 93–100). For satisfaction, the median score for those with at least some 
college education (IQR: 100–100) was 100%, versus 89% (IQR: 78–100) for those with a 
high school education or less.
Characteristics of the Consent Process
Staff members from 14 sites in five countries (Canada [n = 1], South Africa [n = 2], Spain [n 
= 1], Uganda [n = 1], and the United States [n = 9]) completed the consent process 
questionnaire (Table 3). At 13 of the sites, the study coordinator was reported to be one of 
the persons who administered informed consent. Staff members from 12 sites reported not 
using a generic short consent form, and two of these stated that they are not permitted to do 
so by their respective IRBs (U.S. Department of Health and Human Services 2009). Nearly 
all site staff surveyed (n = 13) reported that they allowed patients to defer their enrollment 
decision until a later follow-up visit.
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Site staff reported using different procedures for obtaining consent. For example, staff 
members from two sites read the consent form along with the patient; one had the patients 
silently read the form to themselves. Depending on the patients’ needs, staff members at 
three sites would read the consent form aloud to the patient. The length of time site staff 
members reported for administering consent ranged from less than 1 hour to up to 3 hours.
When asked to provide their overall impressions of the consent process, staff members from 
13 of the 14 sites reported on concerns expressed by study participants. Staff members from 
six sites shared 11 different concerns related to risks and safety (e.g., possible drug side 
effects and toxicity). Staff members from three sites reported six different concerns related 
to study and treatment procedures.
When asked to provide suggestions for improving the consent process, staff members from 
seven sites recommended shorter documents and three suggested creating simpler, more 
understandable consent forms. Additional suggestions included ensuring that the 
administration of the consent process includes adequate time for patients to consider their 
decisions from three site staff members, and the use of supplementary materials such as 
explanation booklets, brochures, posters, or videos by eight site staff members. Site staff 
members also proposed utilizing a questionnaire to assess participant understanding at the 
time of requesting consent, providing a setting free from interruptions during consent 
administration, and providing on-going education on consent topics.
ICAT Scores Related to Consent Processes
Six of the sites completed both the consent process questionnaire and the administration of 
ICATs (n = 44). Three of the consent process questionnaire items and the corresponding 
ICAT scores from Table 3 are provided here. The first explores the question of whether the 
Kampala site’s two-step process might be responsible for their higher comprehension and 
satisfaction results. The other two explore approaches that might be most modifiable in the 
informed consent process.
A. Do You Introduce Principles of Informed Consent Separately from 
Discussion of the Study 29-Specific Informed Consent form? (CRAG 
Hypothesis)—Staff from four sites that administered 44 ICATs reported they discussed 
concepts of informed consent separately from the study-specific informed consent (overall 
comprehension score: 80%, overall satisfaction score: 100%). The Uganda site was one of 
the sites that engaged in this practice. Participants at the Uganda site (n = 30) had a median 
score of 87% on the comprehension scale; however, patients at sites other than Uganda (sites 
[n = 3], patients [n = 14]), where consent principles were discussed separately from the 
study-specific consent form, had a median score of 64% on the comprehension scale. 
Similarly, satisfaction in Uganda was 100%, compared to 78% at other sites with a two-step 
process. Participants at two sites (patients [n = 7]) where principles of consent were not 
reported to be discussed separately from the discussion of the study-specific consent form 
scored 60% for comprehension and 89% for satisfaction.
B. Are Materials Used During the Consent Process to Help Explain the 
Topics?—The median comprehension score for participants at sites (n = 4) where staff 
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used visual aids was 87% (patients [n = 36]), whereas the median comprehension score for 
participants at sites (n = 2) where staff did not use visual aids was 60% (patients [n = 15]). 
Uganda site staff (patients n = 30) used visual aids; participants at this site attained 87% for 
comprehension and 100% for satisfaction. Participants from sites outside of Uganda (n = 3) 
(patients [n = 6]) had a median comprehension score of 73% and a satisfaction score of 89% 
where visual aids were used. At sites where visual aids were not used (sites [n = 2], patients 
[n = 15]), comprehension was 60% and satisfaction was 78%. Visual aids included informal 
written instructions, diagrams, pictures, flyers, a sample package of TB medication, and pills 
on a sheet to demonstrate differences between treatments.
C. How Long Does the Informed Consent Process Take?—The median 
comprehension scores for participants at sites where less than 45 minutes was spent on 
informed consent (sites [n = 2], patients [n = 7]) was 60%, 73% for sites where 60 to 120 
minutes was spent (sites [n = 2], patients [n = 4]), and 87% for the one site (Uganda) where 
120 to 180 minutes was spent (patients [n = 30]). Satisfaction scores varied across time spent 
administering informed consent. The median satisfaction score for participants at sites where 
less than 60 minutes was spent was 89%. Sites where 60 to 120 minutes was spent had a 
median score of 78%, while the score was 100% at the site where 120 to 180 minutes was 
spent.
DISCUSSION
Evaluation of informed consent practices may offer insight for investigators to improve 
consent administration and maximize the alignment of clinical trials’ conduct with the 
principles of respect, beneficence, and justice enunciated in the Belmont Report (National 
Commission for the Protection of Human Subjects of Biomedical and Behavioral Research 
1979). Our pilot evaluation gathered information about the consent process at study sites of 
an international, multisite clinical trial and explored the implementation of an adapted ICAT 
interview tool.
Among the 54 participants in TBTC Study 29 to whom ICATs were administered, median 
scores were high, with 80% (IQR: 67–93) for comprehension and 89% (IQR: 78–100) for 
satisfaction. On average, participants at the Uganda TBTC site scored higher than those at 
other sites on comprehension (87% vs. 64%) and satisfaction (100% vs. 78%). Our 
evaluation found that median comprehension and satisfaction scores were higher among 
persons with more education, consistent with the findings of Breese et al. (2007).
Seven of the ICAT questions on the comprehension scale were of particular interest for the 
purposes of this study. These questions each had an overall score of less than 80% correct or 
favorable response, suggesting potential areas for improvement (Table 2). These seven 
questions are rooted in three components of the Common Rule and FDA 21 CFR 50: (1) 
confidentiality, (2) voluntariness, and (3) alternative procedure options (U.S. Department of 
Health and Human Services 2009; 2013). Not all participants understood that their names 
would not be used for presentations or that study staff could not contact their family and 
friends without approval. Additionally, it was not well understood that they could stop taking 
part in the study at any time or that medical care for TB could be obtained separately from 
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the study, similar to findings from a previous report (Kiguba et al. 2012). It is important to 
note that a participant’s misunderstanding of the right to confidentiality would not 
undermine the effectiveness of this protection; however, the right to withdraw from a study 
is under the volitional control of the participant. As such, it is essential for participants to 
understand that they have rights and can take steps to exercise them.
With one exception, all ICAT satisfaction questions were 80% or higher. The only exception 
was for a question where 33% were either unsure or felt that the papers they signed had too 
much information, which supports the call for shorter informed consent documents. 
Recently, researchers reported the importance of using a “context-specific” approach where 
consent was described using words and analogies that are locally understood (Corneli et al. 
2012). Our evaluation also found that site-specific approaches, including visual aids, 
facilitated understanding of selected topics. Such methods could be evaluated further to 
refine strategies that are culturally appropriate and most effective at communicating the 
consent information and study participants’ rights.
Limitations
Limitations of this study included low and uneven participation in the consent evaluation 
across study sites. This can be attributed to some sites not being staffed for activities 
peripheral to the primary study protocol, investigators being skeptical of the value of 
evaluating their informed consent processes, and differences in TB prevalence and research 
capacity.
The Uganda site enrolled approximately 35% of the participants in the clinical trial (Dorman 
et al. 2012). Of the 54 participants who volunteered to complete an ICAT, 30 (56%) were 
from the Uganda site. The participants from Uganda are not representative of participants at 
other sites.
The revised ICAT used in this evaluation was based on a self-administered form validated by 
Breese et al. (2007). After adapting the statements to be interviewer-administered, the tool 
was not revalidated, and participants may have responded to satisfaction questions in a 
socially desirable manner. In addition, the ICAT was only provided to the participating sites 
in English and study staff simultaneously translated questions for some patients, which had 
the potential to introduce variability.
Additional biases may have been introduced through the use of convenience sampling, 
variability among the staff members who administered consent, the possibility that staff 
members inadvertently led participants in responding to ICAT questions, and the time 
between when informed consent was conducted and when the ICAT was administered. 
Furthermore, with each site submitting a single questionnaire, variability in administrative 
practices amongst multiple staff members at a site may not have been fully captured. Finally, 
not all sites that reported consent practices administered ICATs, limiting opportunities to 
correlate practices with ICAT scores. These factors, along with a small sample size, limit the 
useful depth of analysis, precluding, for example, multivariate analysis.
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Implications
Clinical trial sites expend considerable effort, striving for high comprehension of informed 
consent principles among trial participants. The findings of our pilot evaluation present 
opportunities to improve the consent process and the assessment of the process itself, 
particularly more focused training, including the need to reemphasize specific components 
of the Common Rule and FDA 21 CFR 50 multiple times throughout a study (U.S. 
Department of Health and Human Services 2009; 2013).
Observers have speculated that a tool similar to the ICAT could be used throughout the study 
to reemphasize the rights and protections afforded to study participants. Adapting an ICAT 
for patient-level, real-time use would require a development and validation process. A more 
immediate course of action could include training site staff members to routinely assess 
participants’ comprehension both during and after presentation of specific components of 
the Common Rule and FDA 21 CFR 50 and evaluating the impact of the educational 
intervention.
Our pilot evaluation provides insights for a more robust evaluation of the consent process in 
future multicenter clinical trials. Specifically, it may be beneficial to incorporate the 
evaluation of the consent process into the main study protocol to ensure all sites’ 
participation; dedication of resources to evaluation activities; and the systematic collection 
of data. Additionally, it may be advantageous to develop a tool to quantify site-specific 
consent practices to help pinpoint specific practices associated with higher comprehension 
and satisfaction.
As seen in this pilot evaluation, further investigation is needed to identify reasons for the 
Uganda site’s higher comprehension and satisfaction scores. While this evaluation supported 
CRAG’s hypothesis of comprehension and satisfaction being higher at the TBTC site in 
Uganda, it did not support the additional hypothesis that a two-part informed consent 
process would result in higher comprehension among participants outside of Uganda. A 
median satisfaction score of 100% from participants surveyed at the Ugandan site is 
impressive, yet further evaluation is needed to determine whether the following influenced 
the score: cultural factors, the influence of a staff-administered satisfaction survey on patient 
responses, patients’ perceptions of the care available in a research setting compared to 
regular program care, the time period between enrollment and ICAT administration, length 
of consent process, and median age of the participants.
The IRBs at many sites declined to take advantage of the short consent form as permitted by 
the Code of Federal Regulations (U.S. Department of Health and Human Services 2009; 
2013). Future evaluation efforts of the consent process could include using a long version of 
the consent form as the “written summary of what is to be said” coupled with use of the 
short form for all participants. The short form could also be used throughout the study to 
reinforce important topics. When considering the benefits that may be derived from use of 
the short consent form, researchers must also consider additional resources that are needed. 
For example, per regulations, another individual may be needed to witness the oral 
presentation (bU.S. Department of Health and Human Services 2011b).
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Finally, while ethical regulations stress the importance of comprehension, participant 
satisfaction with the informed consent process also deserves consideration. The ICAT’s 
satisfaction questions focus on actions that, in theory, contribute to comprehension. This 
calls attention to the challenge of balancing these two domains in order to achieve a 
“successful” informed consent from both the participants’ and investigators’ perspectives.
CONCLUSIONS
This project presents an approach to how the quality of the informed consent process may be 
systematically evaluated and illustrates logistical issues to consider when working with 
persons who possess varying levels of education. Overall, this pilot evaluation found high 
levels of participant comprehension and satisfaction with the consent process at sites 
participating in an international clinical trial.
In addition, both comprehension and satisfaction were higher in Uganda, which was 
consistent with CRAG’s original hypothesis. However, with only small numbers of ICATs, 
the underlying reasons for these higher scores could not be determined. Based on the scores 
of individual ICAT questions, three components of the Common Rule and FDA 21 CFR 50 
may need additional emphasis when sites review consent information with potential 
participants: confidentiality, voluntary participation, and alternative procedure options. 
Furthermore, re-review of rights and procedures throughout study participation could prove 
beneficial.
The staff at study sites also helped identify opportunities to improve the informed consent 
process, such as creating educational materials to facilitate explanation of consent concepts, 
especially those for which the study participants demonstrated lower comprehension. 
Additionally, greater acceptance of the short consent process form may address participant 
concerns that there was too much information in the papers they signed.
Findings from this pilot evaluation will assist in the design of a larger study and in the 
revision of data collection tools. Continuing this work may provide insights to improve 
comprehension and satisfaction with the informed consent process.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Analysis groups for pilot informed consent evaluation.
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Table 2
ICAT* Questions: Proportion of Correct/Favorable Responses by Common Rule
Correct/Favorable Response
Total
(n = 54)/n 
(%) Common Rule Component
Comprehension
  1 Are you taking part in a research study? Yes 52 (96) (1) Research
  3 Now that you are in the study, do you have to stay in it 
even if you do not want to?
No 43 (80) (8) Voluntariness
  5 Did you have to sign the papers because your doctor gave 
them to you?
No 43 (80) (8) Voluntariness
  6 Can the study staff contact your family or friends 
without your approval?
No 28 (52) (5) Confidentiality
  9 May your private information from this study be seen 
by any medical person?
No 23 (43) (5) Confidentiality
11 Can you stop taking part in this study at any time? Yes 40 (74) (8) Voluntariness
13 Will you be told about any important changes in this 
study?
Yes 49 (91) (b) Additional Elements:
(5) Significant new findings
14 Can your name be used for presentations of this 
study?
No 42 (78) (5) Confidentiality
16 Does the study staff need your approval to contact 
your family and friends?
Yes 36 (67) (5) Confidentiality
18 Do you know whom you can contact if you have a 
question about this study?
Yes 50 (93) (7) Questions
19 Can you still get care for your illness, even if you don’t 
want to be in this study?
Yes 47 (87) (4) Alternative Procedures
21 Could the treatment you are receiving cause you to have 
side effects?
Yes 46 (85) (2) Risks
22 Must you be in the study to get medical care for 
tuberculosis?
No 35 (65) (4) Alternative Procedures
23 Will this study be six to nine months long? Yes 50 (93) (1) Research
24 Is the treatment you are receiving in this study your 
only option?
No 39 (72) (4) Alternative Procedures
Satisfaction
  2 Was there too much information in the papers you 
signed?
No 36 (67)
  4 Did someone explain the study to you in words that you 
understood?
Yes 52 (96)
  7 Were there questions you wanted to ask about this study 
but did not ask?
No 43 (80)
  8 Did you sign the papers to be part of this study without 
completely reading them?
No 43 (80)
10 Did you have enough time to read the papers you signed 
to be part of this study?
Yes 47 (87)
12 Did the study staff answer your questions about this 
study?
Yes 48 (89)
15 Were you confused by the papers you signed for this 
study?
No 51 (94)
17 Did you need more time to read the papers you signed to 
be part of this study?
No 47 (87)
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Correct/Favorable Response
Total
(n = 54)/n 
(%) Common Rule Component
20 Do you have a copy of all the papers you signed? Yes 51 (94)
Bolded questions indicate questions with <80% of the TOTAL responding with correct or favorable response.
*
ICAT: Informed Consent Assessment Tool.
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